Skip to content

Dental care REsistance prevention and Antibiotic prescribing Modification ? the DREAM trial

Dental care REsistance prevention and Antibiotic prescribing Modification ? A cluster-randomised controlled trial in German dental primary care

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN09576376
Enrollment
46000
Registered
2013-04-30
Start date
2012-09-01
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic prescribing in dental primary care Not Applicable

Interventions

The intervention involves elements of local consensus formation, antibiotic prescription feedback, and communication training. Training of the intervention group will be organized within small group s

Sponsors

Medical University of Rostock (Universitätsmedizin Rostock) (Germany)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Primary care dentists and their male and female patient population of all ages in Mecklenburg-Western Pomerania (Germany). 2. Patients aged 18 years or older seen by their dentists for an odontogenic infection or abscess, and who have not been treated for such a condition in the previous six months, are eligible for being recruited into the subgroup (swabs).

Exclusion criteria

Exclusion criteria: To investigate antibiotic prescribing the DREAM trial includes the entire patient population of participating dental practices. Exclusion criteria for patients in the subgroup include: 1. Younger than 18 years 2. Not being able to give informed consent (e.g. in case of dementia) 3. Consulting the dentist during the emergency service 4. Suffering from immunosuppression or malignoma 5. Having a disease-related life expectancy of less than 12 months

Design outcomes

Primary

MeasureTime frame
Dentists? overall antibiotic prescription rate. Data is collected over a six-month baseline period (T0), at T1 (month 10 to 15), and T2 (month 19 to 24)

Secondary

MeasureTime frame
Secondary outcomes for the subgroup: 1. Severity of illness 2. Pain (VAS) 3. Duration of treatment 4. Re-consultation rate 5. Use of medical services 6. Adverse effects related to antibiotic treatment

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 21, 2026